Efficacy issues with antidepressants

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 6, 1997, Pages 32-39

  Fawcett, Jan ^a,b   Barkin, Robert L ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b Rush Institute for Mental Well Being   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; DYSEREL; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; FUNCTIONAL ASSESSMENT; HUMAN; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TREATMENT OUTCOME;

ABSENTEEISM; AGE FACTORS; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS; DEPRESSIVE DISORDER; FOLLOW-UP STUDIES; HUMANS; IMIPRAMINE; MIANSERIN; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WORK;

EID: 0030818928     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995;10:3-9
2. Angst J, Scheidegger P, Stabl M. Efficacy of moclobemide in different patient groups: results of new subscales of the Hamilton Depression Rating Scale. Clin Neuropharmacol 1993;16(suppl 2):S55-S62
3. Davis JM, Wang Z, Janicak PG. A quantitative analysis of clinical drug trials for the treatment of affective disorders. Psychopharmacol Bull 1993;29: 175-181
4. Coryell W, Coppen A, Zeigler VE, et al. Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples. Psychol Med 1982;12:135-139
5. Boyer WF, Feighner JP. Clinical significance of early non-response in depressed patients. Depression 1994;2:32-35
6. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry 1995;152: 1500-1503
7. Bremner JD, Abrahams LM, Crupie JE. et al. Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. J Clin Psychiatry 1984;45(4, sec 2):56-59
8. Derivan A, Entsuah AR, Kikta D. Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull 1995;31:439-447
9. Gasperini M, Gatti F, Bellini L, et al. Perspectives in clinical psychopharmacology of amitriptyline and fluvoxamine: a double-blind study in depressed inpatients. Neuropsychobiology 1992;26:186-192
10. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-525
11. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorders. Psychopharmacol Bull 1990;26:191-196
12. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of ORG 3770 in depressed outpatients. J Affect Disord 1995;34:165-171
13. Montgomery SA. Are 2-week trials sufficient to indicate efficacy? Psychopharmacol Bull 1995;31:41-44
14. Gerson SC, Plotkin DA, Jarvik LF. Antidepressant drug studies, 1964 to 1986: empirical evidence for aging patients. J Clin Psychopharmacol 1988; 8:311-322
15. Dunner DL. Therapeutic considerations in treating depression in the elderly. J Clin Psychiatry 1994;55(12, suppl):48-58
16. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Human Psychopharmacology 1995;10: S125-S133
17. Zivkov M, de Jongh. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Human Psychopharmacology 1995;10:173-180
18. Einarson TR, Arikian S, Sweeney S, et al. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995;17:136-153
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987
20. Zivkov M, Roes KCB, Pols AG. Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Human Psychopharmacology 1995;10:S135-S145
21. Bremner JD, Smith WT. Org 3770 vs amitriptyline in the continuation treatment of depression: a placebo controlled trial. Eur J Psychiatry 1996; 10:5-15
22. Mullin J, Lodge A, Bennie E, et al. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol (Oxf) 1996;10:235-240
23. Wheatley D, Kremer C. A randomized, double-blind comparison of mirtazapine and fluoxetine in patients with major depression. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 20, 1997; San Diego, Calif. Abstract NR208:124
24. Elkin I, Shea MT, Watkins JT, et al. National Institute of Mental Health treatment of depression collaborative research program: general effectiveness of treatments. Arch Gen Psychiatry 1989;46:971-982
25. Workman EA, Short DD. Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis. J Clin Psychiatry 1993; 54:5-12
26. Byerley WF, Reimherr FW, Wood DR, et al. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988;8:112-115
27. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry 1985;46(3, sec 2):53-58
28. Mintz J, Mintz LI, Arruda MJ, et al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768
29. Frank E, Kupfer DJ, Perel JM, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47: 1093-1099
30. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms: results from a placebo-controlled trial. Drug Invest 1994;8:339-344
31. Dunbar GC, Cohn JB, Fabre LF, et al. A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 1991;159: 394-398
32. Fawcett J, Marcus RN, Anton SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995;56(suppl 6):37-42